HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

2021 ◽  
Vol 19 (3.5) ◽  
pp. HSR21-073
Author(s):  
Weijia Wang ◽  
Edward Li ◽  
Kim Campbell ◽  
Ali McBride
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Real World ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Medicare Claims ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non-hodgkin's lymphoma

2009 ◽  
Vol 23 (6) ◽  
pp. 387-393 ◽  
Author(s):  
Karen Brajão de Oliveira ◽  
Julie Massayo Maeda Oda ◽  
Julio Cesar Voltarelli ◽  
Thiago Franco Nasser ◽  
Mario Augusto Ono ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA

2021 ◽  
Author(s):  
Ahmed Shelbaya ◽  
John M Kelton ◽  
Jeffrey Thompson ◽  
Jose MJ Alvir ◽  
Martine C Maculaitis ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Hodgkin’S Lymphoma ◽  
Reference Product ◽  
Lymphocytic Leukemia ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Usa ◽  
Oncology Practice

Aim: To describe treatment patterns and patient and provider characteristics associated with the recently introduced biosimilar rituximab-pvvr. Methods: This retrospective analysis included adult patients with one or more claims for rituximab-pvvr, with an index date of 23 January 2020 and a study period covering 1 January 2019–31 July 2020. Results: Of 249 patients included, the most common rituximab-pvvr indications were non-Hodgkin’s lymphoma (77.5%) and chronic lymphocytic leukemia (11.2%). Some patients with non-Hodgkin’s lymphoma (42.5%) and chronic lymphocytic leukemia (39.3%) switched to rituximab-pvvr from the reference product or another rituximab biosimilar. Most patients were aged ≥65 years (63.5%) and were male (54.6%). Most (59.0%) rituximab-pvvr prescribers practiced in the south of the USA. Conclusion: Utilization occurred in approved and extrapolated indications. These preliminary findings suggest switching between reference product and rituximab biosimilars; rituximab-pvvr combination regimens are being adopted in real-world oncology practice.

Sign in / Sign up

Export Citation Format

Share Document